Literature DB >> 21279095

The safety of blood transfusions.

M L Schroeder, H L Rayner.   

Abstract

Blood transfusion therapy carries a small risk of complications-usually minor-which include allergic reactions, hemolysis, and the transmission of infections. Fatal hemolytic transfusion reactions are rare and are usually due to human error resulting in administration of ABO incompatible blood. Viral hepatitis (usually non-A, non-B) remains the major infectious complication, with a risk of two to five percent. The transmission by transfusion of AIDS has also been reported, but the risk is much lower-about 0.001%. As yet, no blood substitute is available for clinical use. Routine hepatitis B testing and the volunteer blood donor system ensure that transfusion risks are minimal in Canada. By limiting transfusion to those patients who truly need it, a high therapeutic index can be maintained.

Entities:  

Year:  1984        PMID: 21279095      PMCID: PMC2154235     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN: 0008-350X            Impact factor:   3.275


  17 in total

1.  Post-transfusion hepatitis in Australia. Report of the Australian Red Cross study.

Authors:  Y E Cossart; S Kirsch; S L Ismay
Journal:  Lancet       Date:  1982-01-23       Impact factor: 79.321

Review 2.  Modified hemoglobin solution as a resuscitation fluid.

Authors:  F DeVenuto
Journal:  Vox Sang       Date:  1983-03       Impact factor: 2.144

3.  Strong new candidate for AIDS agent.

Authors:  J L Marx
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

4.  Enzyme-linked immunoassay for hepatitis B surface antigen. An evaluation of commercial test kits.

Authors:  N Nath; R Y Dodd; C T Fang
Journal:  Transfusion       Date:  1983 Jan-Feb       Impact factor: 3.157

5.  Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors.

Authors:  H J Alter; P V Holland; R H Purcell; J J Lander; S M Feinstone; A G Morrow; P J Schmidt
Journal:  Ann Intern Med       Date:  1972-11       Impact factor: 25.391

6.  The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, Fluosol-DA.

Authors:  K K Tremper; A E Friedman; E M Levine; R Lapin; D Camarillo
Journal:  N Engl J Med       Date:  1982-07-29       Impact factor: 91.245

7.  Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS.

Authors:  M G Sarngadharan; M Popovic; L Bruch; J Schüpbach; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

8.  Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS).

Authors:  F Barré-Sinoussi; J C Chermann; F Rey; M T Nugeyre; S Chamaret; J Gruest; C Dauguet; C Axler-Blin; F Vézinet-Brun; C Rouzioux; W Rozenbaum; L Montagnier
Journal:  Science       Date:  1983-05-20       Impact factor: 47.728

Review 9.  Current status of erythrocyte substitutes.

Authors:  G P Biro
Journal:  Can Med Assoc J       Date:  1983-08-01       Impact factor: 8.262

10.  Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS.

Authors:  R C Gallo; S Z Salahuddin; M Popovic; G M Shearer; M Kaplan; B F Haynes; T J Palker; R Redfield; J Oleske; B Safai
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.